These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33203642)

  • 1. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
    Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
    Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DLL3: an emerging target in small cell lung cancer.
    Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
    J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
    Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
    Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
    Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
    Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
    Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
    J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
    Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
    Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
    Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
    EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating
    Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
    Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
    Paz-Ares L; Champiat S; Lai WV; Izumi H; Govindan R; Boyer M; Hummel HD; Borghaei H; Johnson ML; Steeghs N; Blackhall F; Dowlati A; Reguart N; Yoshida T; He K; Gadgeel SM; Felip E; Zhang Y; Pati A; Minocha M; Mukherjee S; Goldrick A; Nagorsen D; Hashemi Sadraei N; Owonikoko TK
    J Clin Oncol; 2023 Jun; 41(16):2893-2903. PubMed ID: 36689692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
    Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
    Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
    Chou J; Egusa EA; Wang S; Badura ML; Lee F; Bidkar AP; Zhu J; Shenoy T; Trepka K; Robinson TM; Steri V; Huang J; Wang Y; Small EJ; Chan E; Stohr BA; Ashworth A; Delafontaine B; Rottey S; Cooke KS; Hashemi Sadraei N; Yu B; Salvati M; Bailis JM; Feng FY; Flavell RR; Aggarwal R
    Cancer Res; 2023 Jan; 83(2):301-315. PubMed ID: 36351060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
    Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
    Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.